Editor-In recent years, numerous single case reports and a few series of retrospective cohorts of patients have been published dealing with serious bleeding and massive transfusion demands in whom recombinant activated factor VII concentrate (rFVIIa) has been tried as salvage therapy. In the absence of controlled clinical studies, practice has arisen in many places where rFVIIa has been adopted as part of the haemostasis armamentarium for treatment of uncontrollable bleeding after trauma and surgery.
We presented data recently in the British Journal of Anaesthesia that illustrate a hypocoagulable state of blood after exposure to haemodilution with various colloid plasma expanders, and our experiments point to a relatively beneficial change in the dynamic whole blood clotting profile if such blood is substituted with fibrinogen concentrate.
1 More recently, Brummel-Ziedins and colleagues have supplemented our findings by demonstrating that haemodilution with colloids causes diminished platelet Correspondence activation, compromised fibrin polymerization and reduced whole blood thrombin generation capacity. 2 We have undertaken additional experimental work in our laboratory to address the question of whether colloid-induced coagulopathy could possibly be reversed with the aid of rFVIIa by testing ex vivo two dose levels of rFVIIa and a buffer control for their possible influence on coagulopathy induced by various levels of haemodilution with HES 130=4. Without haemodilution, rFVIIa, at the two dose-levels tested, normalized the prolonged clotting time in experiments with saline and HES 130=0.4. However, following haemodilution with colloid to a level of 25% or more, rFVIIa does not appear to improve the diminished maximum coagulation velocity of whole blood clot formation (Fig. 1) .
Recently, a randomized clinical trial on 300 trauma patients demonstrated that rFVIIa administered to bluntly traumatized patients significantly reduced the transfusion requirements as compared with placebo.
3 Trauma patients with shock often receive volume substitution initially with quite large amounts of plasma expanders to maintain sufficient blood pressure. In view of this, our new data contribute to understanding the limited effect on haemostasis if rFVIIa is administered after large volumes of colloid HES 130=0.4. The critical issue here is the lack of improvement of the velocity of clot formation. Our original paper 1 shows that addition of fibrinogen increases the velocity of clot formation. In view of this, severe bleeding occurring shortly after volume substitution with HES may be managed better with fibrinogen before rFVIIa. We feel the interpretation of the results deserves a more detailed appraisal. The INVOS 4100S gives a single readout for regional cerebral oxygen saturations using an algorithm based upon the Beer-Lambert law. In this study, both subject groups showed no change in Sj O 2 but a decrease in Sc O 2 . The disparity in readings could be consistent with a systematic error. We suspect the algorithm incorporated within the INVOS 4100S may not take into account the fall in haemoglobin concentration. The fall in oxygenation index has actually been found to correlate with blood loss in healthy volunteers.
2
Cerebral oximetry does not take into account changes in the relative proportions of blood in the arterial or venous part of a capillary bed. The proportion of arterial blood in the cerebral capillaries had been estimated at 28%.
3 Hypoxia can induce changes in the cerebral arterial to venous volume ratio 4 and it would not be unreasonable to assume that other factors may also affect the cerebral arterial to venous volume ratio. A change in the relative proportions of arterial and venous blood in the cerebral capillaries may alter cerebral oximetry readings without a 'real' effect on cerebral tissue oxygenation.
We have previously expressed concerns 5 about the interpretation of cerebral oximetry in a clinical setting, and Yoshitani's paper has raised a most important issue concerning the effect of haemodilution upon the readings. A change in Sc O 2 could be attributable to many factors. In the clinical setting, changes in Sc O 2 should be interpreted with caution, particularly when there is significant blood loss. Previous studies have demonstrated that various factors, such as haemoglobin concentrations, extracranial blood flow and changes in cerebral arterial to venous blood volume ratio had an effect on near infrared spectroscopy measurements.
7-9 However, it was difficult to evaluate the degree of effects of such factors on Sc O 2 values. We have only investigated the effect of haemoglobin concentration
